These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31480747)

  • 1. Plasma Membrane-Associated Restriction Factors and Their Counteraction by HIV-1 Accessory Proteins.
    Ramirez PW; Sharma S; Singh R; Stoneham CA; Vollbrecht T; Guatelli J
    Cells; 2019 Sep; 8(9):. PubMed ID: 31480747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
    Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
    Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
    Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.
    Trautz B; Pierini V; Wombacher R; Stolp B; Chase AJ; Pizzato M; Fackler OT
    J Virol; 2016 Dec; 90(23):10915-10927. PubMed ID: 27681140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
    Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
    PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.
    Bego MG; Cong L; Mack K; Kirchhoff F; Cohen ÉA
    J Virol; 2016 Nov; 90(22):10236-10246. PubMed ID: 27581991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
    Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
    Lau D; Kwan W; Guatelli J
    J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
    Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
    Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
    Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
    Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
    Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
    PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
    Arias JF; Iwabu Y; Tokunaga K
    Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes.
    Vassena L; Giuliani E; Koppensteiner H; Bolduan S; Schindler M; Doria M
    J Virol; 2015 May; 89(10):5687-700. PubMed ID: 25822027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
    Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
    J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and Persistence.
    Sugden SM; Bego MG; Pham TN; Cohen ÉA
    Viruses; 2016 Mar; 8(3):67. PubMed ID: 26950141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
    Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.